Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 634 | 127 | 493 |
| Samples | 589 | 120 | 459 |
| Peptides | 409 | 82 | 339 |
Function
CD93 · CD93 molecule
The protein encoded by this gene is a cell-surface glycoprotein and type I membrane protein that was originally identified as a myeloid cell-specific marker. The encoded protein was once thought to be a receptor for C1q, but now is thought to instead be involved in intercellular adhesion and in the clearance of apoptotic cells. The intracellular cytoplasmic tail of this protein has been found to interact with moesin, a protein known to play a role in linking transmembrane proteins to the cytoskeleton and in the remodelling of the cytoskeleton. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000246006 | Q9NPY3 | 634 | 409 |
Gene Properties
Recurrent Mutations
All 409 amino-acid changes on canonical ENST00000246006 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in CD93 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in CD93 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Chronic Myelogenous Leukemia | 3/25 12% | 0/0 0% |
| T-Lymphoblastic Leukemia | 3/40 8% | 0/0 0% |
| Unknown | 2/10 20% | 0/29 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 6/133 5% |
| Melanoma | 9/210 4% | 78/1899 4% |
| Glioblastoma | 4/98 4% | 0/0 0% |
| Non-Small Cell Lung Carcinoma | 27/304 9% | 30/1390 2% |
| Endometrial Carcinoma | 3/42 7% | 18/612 3% |
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| Colorectal Carcinoma | 7/143 5% | 65/3239 2% |
| Gastric Carcinoma | 5/74 7% | 34/1809 2% |
| Squamous Cell Lung Carcinoma | 5/57 9% | 12/810 1% |
| Other Solid Cancers | 1/94 1% | 30/1515 2% |
| Adrenocortical Carcinoma | 2/3 67% | 0/112 0% |
| Small Cell Lung Carcinoma | 3/9 33% | 9/752 1% |
| Pheochromocytoma and Paraganglioma | 0/0 0% | 1/71 1% |
| Bladder Carcinoma | 3/58 5% | 11/956 1% |
| Cervical Carcinoma | 0/35 0% | 6/422 1% |
| Plasma Cell Myeloma | 2/44 5% | 2/305 1% |
| Thyroid Gland Carcinoma | 1/45 2% | 17/1592 1% |
| Ovarian Carcinoma | 5/109 5% | 7/998 1% |
| Pancreatic Carcinoma | 4/89 4% | 13/1611 1% |
| Non-Cancerous | 1/104 1% | 8/830 1% |
| Esophageal Squamous Cell Carcinoma | 5/51 10% | 18/2550 1% |
| Burkitts Lymphoma | 2/32 6% | 0/196 0% |
| Neuroendocrine Tumour | 3/154 2% | 3/577 1% |
| Biliary Tract Carcinoma | 0/54 0% | 8/950 1% |
| Glioma | 1/52 2% | 16/2127 1% |
| Hepatocellular Carcinoma | 2/46 4% | 15/2210 1% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
Mutation Distribution
Where CD93 is mutated · all tissues, split by cell line vs tissue
How many mutations in CD93 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 634 mutations in CD93
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|